As a late clinical-stage biopharmaceutical company focused on oncology, our business model is to in-license novel compounds, develop them through clinical stages, and then seek to commercialize them through out-licensing arrangements with biotechnology and pharmaceutical companies or evaluating, on a case-by-case basis, the commercialization of our therapeutic candidates independently.

Our lead program, motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in stem-cell mobilization for autologous bone-marrow transplantation and has reported positive results from pharmacoeconomic studies. These outstanding results support the goal of motixafortide becoming the standard of care mobilization agent in autologous bone-marrow transplantation, and in this regard, after a successful pre-NDA meeting with the FDA, we are currently preparing an NDA submission in more


Upcoming Events View all

There are currently no events to display.

I.R. Contacts

John Lacey, MS, MBA
Head of Corporate Communications & Investor Relations